We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aegis Therapeutics LLC Awarded Patent for Parathyroid Hormone (PTH) Peptide Drug Formulations

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aegis Therapeutics LLC Awarded Patent for Parathyroid Hormone (PTH) Peptide Drug Formulations"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Examples of approved PTH drugs include Eli Lilly's Forteo® sold worldwide and NPS's Preotact® licensed by Nycomed for Ex-US sales. PTH 1-34 (teriparatide) injection is indicated for the treatment of postmenopausal women with osteoporosis, and to increase bone mass in men with primary or hypogonadal osteoporosis.

This patent has been exclusively licensed to Azelon Pharmaceuticals. All currently approved PTH drug formulations require daily injection. In contrast, Azelon has reported clinical results demonstrating that formulations of teriparatide based upon Aegis' Intravail®/ProTek® show excellent nasal bioavailability offering the prospect of a "first in class" non-injectable PTH drug. Non-injectable dosage forms of previously injectable-only drugs provide greater patient convenience and acceptance, improved compliance, and avoidance of needle-stick injury and disposal problems associated with the use of needles, paving the way to increased market share and substantial growth in overall product sales.
Licenses for non-invasive delivery and stabilization of human growth hormone, GLP-1 analogs, and other drugs are currently available from Aegis with additional patent issuances to be announced shortly.